Published November 2014 | Version v1
Journal article

The research progress of alpha-emitting radionuclides targeted therapy

  • 1. Chengdu Radiopharmaceutical Engineering Technology Research Center, Chengdu (China)
  • 2. Chengdu YUNKE Pharmaceutical Co., LTD., Chengdu (China)
  • 3. State Key Laboratory of Biotherapy of Sichuan University, Chengdu (China)

Description

Alpha-emitting radionuclides provide effective cell-killing properties in vivo and have been shown to be effective in cancer treatment. Its short-range make little effect on normal tissues, thus alpha-emitting radionuclides drugs is one of the important research focus areas and radiopharmaceutical research. The excellent nature of the radionuclide (right half life, ray energy, etc.), stable supply of high purity nuclides, suitable radionuclide carrier base and excellent kinetics in vivo are necessary to the production and research of alpha-emitting radionuclides. At present, the alpha-emitting radionuclides include 223Ra, 225Ac, 213Bi, 211At, 212Bi, 149Tb and 227Th were investagated. The preparation and sources of the above radionuclides and the latest developments for targeted cancer therapy were described. The existing problems, status and clinical application were briefly discussed. (authors)

Additional details

Publishing Information

Journal Title
Journal of Isotopes
Journal Volume
27
Journal Issue
4
Journal Page Range
p. 241-250
ISSN
1000-7512

Optional Information

Notes
6 figs., 1 tab., 48 refs.